Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SAR1B

Gene summary for SAR1B

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SAR1B

Gene ID

51128

Gene namesecretion associated Ras related GTPase 1B
Gene AliasANDD
Cytomap5q31.1
Gene Typeprotein-coding
GO ID

GO:0002376

UniProtAcc

Q9Y6B6


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
51128SAR1BLZE2THumanEsophagusESCC1.54e-025.26e-010.082
51128SAR1BLZE4THumanEsophagusESCC9.05e-215.19e-010.0811
51128SAR1BLZE5THumanEsophagusESCC1.60e-043.45e-010.0514
51128SAR1BLZE7THumanEsophagusESCC2.58e-052.46e-010.0667
51128SAR1BLZE8THumanEsophagusESCC8.18e-093.55e-010.067
51128SAR1BLZE20THumanEsophagusESCC2.48e-092.49e-010.0662
51128SAR1BLZE22THumanEsophagusESCC6.47e-065.26e-010.068
51128SAR1BLZE24THumanEsophagusESCC1.92e-309.19e-010.0596
51128SAR1BLZE21THumanEsophagusESCC1.79e-053.59e-010.0655
51128SAR1BLZE6THumanEsophagusESCC2.75e-114.58e-010.0845
51128SAR1BP1T-EHumanEsophagusESCC1.31e-033.56e-010.0875
51128SAR1BP2T-EHumanEsophagusESCC9.28e-274.48e-010.1177
51128SAR1BP4T-EHumanEsophagusESCC2.28e-357.25e-010.1323
51128SAR1BP5T-EHumanEsophagusESCC1.34e-438.54e-010.1327
51128SAR1BP8T-EHumanEsophagusESCC2.09e-193.35e-010.0889
51128SAR1BP9T-EHumanEsophagusESCC5.54e-234.33e-010.1131
51128SAR1BP10T-EHumanEsophagusESCC5.62e-232.62e-010.116
51128SAR1BP11T-EHumanEsophagusESCC3.96e-175.98e-010.1426
51128SAR1BP12T-EHumanEsophagusESCC3.43e-295.08e-010.1122
51128SAR1BP15T-EHumanEsophagusESCC4.32e-408.62e-010.1149
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00901142LiverHCCCOPII-coated vesicle budding27/795829/187231.28e-083.14e-0727
GO:005165021LiverHCCestablishment of vesicle localization103/7958161/187232.94e-086.69e-07103
GO:00481991LiverHCCvesicle targeting, to, from or within Golgi20/795821/187234.57e-077.50e-0620
GO:005164821LiverHCCvesicle localization107/7958177/187231.05e-061.57e-05107
GO:00325272LiverHCCprotein exit from endoplasmic reticulum36/795848/187234.85e-066.10e-0536
GO:000690311LiverHCCvesicle targeting34/795845/187236.75e-068.08e-0534
GO:000690111LiverHCCvesicle coating16/795817/187231.15e-051.31e-0416
GO:001988212LiverHCCantigen processing and presentation65/7958106/187237.06e-056.37e-0465
GO:00482071LiverHCCvesicle targeting, rough ER to cis-Golgi12/795813/187232.73e-041.98e-0312
GO:00482081LiverHCCCOPII vesicle coating12/795813/187232.73e-041.98e-0312
GO:004800212LiverHCCantigen processing and presentation of peptide antigen40/795862/187233.84e-042.62e-0340
GO:000247411LiverHCCantigen processing and presentation of peptide antigen via MHC class I21/795828/187234.94e-043.23e-0321
GO:00708612LiverHCCregulation of protein exit from endoplasmic reticulum20/795827/187238.85e-045.23e-0320
GO:004819315Oral cavityOSCCGolgi vesicle transport209/7305296/187231.39e-286.30e-26209
GO:003238615Oral cavityOSCCregulation of intracellular transport218/7305337/187236.91e-221.41e-19218
GO:005165610Oral cavityOSCCestablishment of organelle localization239/7305390/187232.46e-193.31e-17239
GO:003315718Oral cavityOSCCregulation of intracellular protein transport155/7305229/187231.05e-181.28e-16155
GO:004325420Oral cavityOSCCregulation of protein-containing complex assembly255/7305428/187232.94e-183.15e-16255
GO:00160508Oral cavityOSCCvesicle organization189/7305300/187232.40e-172.14e-15189
GO:00068888Oral cavityOSCCendoplasmic reticulum to Golgi vesicle-mediated transport97/7305130/187231.42e-161.15e-1497
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04141211EsophagusESCCProtein processing in endoplasmic reticulum147/4205174/84653.29e-221.10e-195.64e-20147
hsa0513428EsophagusESCCLegionellosis42/420557/84651.83e-046.90e-043.53e-0442
hsa04141310EsophagusESCCProtein processing in endoplasmic reticulum147/4205174/84653.29e-221.10e-195.64e-20147
hsa0513436EsophagusESCCLegionellosis42/420557/84651.83e-046.90e-043.53e-0442
hsa0414114LiverCirrhoticProtein processing in endoplasmic reticulum114/2530174/84651.16e-229.67e-215.96e-21114
hsa0513412LiverCirrhoticLegionellosis28/253057/84651.71e-038.01e-034.94e-0328
hsa0414115LiverCirrhoticProtein processing in endoplasmic reticulum114/2530174/84651.16e-229.67e-215.96e-21114
hsa0513413LiverCirrhoticLegionellosis28/253057/84651.71e-038.01e-034.94e-0328
hsa0414122LiverHCCProtein processing in endoplasmic reticulum146/4020174/84657.34e-242.46e-211.37e-21146
hsa0414132LiverHCCProtein processing in endoplasmic reticulum146/4020174/84657.34e-242.46e-211.37e-21146
hsa0414130Oral cavityOSCCProtein processing in endoplasmic reticulum143/3704174/84656.82e-262.28e-231.16e-23143
hsa0513425Oral cavityOSCCLegionellosis42/370457/84654.18e-062.15e-051.10e-0542
hsa04141113Oral cavityOSCCProtein processing in endoplasmic reticulum143/3704174/84656.82e-262.28e-231.16e-23143
hsa05134111Oral cavityOSCCLegionellosis42/370457/84654.18e-062.15e-051.10e-0542
hsa04141210Oral cavityLPProtein processing in endoplasmic reticulum113/2418174/84658.74e-245.82e-223.76e-22113
hsa0513426Oral cavityLPLegionellosis33/241857/84653.29e-063.23e-052.08e-0533
hsa0414138Oral cavityLPProtein processing in endoplasmic reticulum113/2418174/84658.74e-245.82e-223.76e-22113
hsa0513435Oral cavityLPLegionellosis33/241857/84653.29e-063.23e-052.08e-0533
hsa0414128ProstateBPHProtein processing in endoplasmic reticulum97/1718174/84652.37e-251.30e-238.07e-2497
hsa0513420ProstateBPHLegionellosis22/171857/84651.10e-034.99e-033.09e-0322
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SAR1BinsertionFrame_Shift_Insnovelc.486_487insCp.Ile163HisfsTer17p.I163Hfs*17Q9Y6B6protein_codingTCGA-BH-A0HF-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexSD
SAR1BinsertionIn_Frame_Insnovelc.485_486insGTCTCAACGTTCAGGCTTACTCAGAGATTTGATTGCp.Ser162delinsArgSerGlnArgSerGlyLeuLeuArgAspLeuIleAlap.S162delinsRSQRSGLLRDLIAQ9Y6B6protein_codingTCGA-BH-A0HF-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexSD
SAR1BSNVMissense_Mutationc.413N>Ap.Arg138Lysp.R138KQ9Y6B6protein_codingtolerated(0.72)benign(0)TCGA-LP-A5U3-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
SAR1BSNVMissense_Mutationnovelc.301N>Ap.Asp101Asnp.D101NQ9Y6B6protein_codingdeleterious(0)probably_damaging(0.99)TCGA-VS-A958-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
SAR1BSNVMissense_Mutationnovelc.272C>Ap.Pro91Hisp.P91HQ9Y6B6protein_codingdeleterious(0.05)benign(0.243)TCGA-A5-A1OF-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SAR1BSNVMissense_Mutationc.316G>Ap.Glu106Lysp.E106KQ9Y6B6protein_codingtolerated(0.07)benign(0.013)TCGA-AP-A0LM-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycisplatinSD
SAR1BSNVMissense_Mutationnovelc.523N>Tp.Val175Phep.V175FQ9Y6B6protein_codingdeleterious(0)possibly_damaging(0.908)TCGA-AP-A1DV-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
SAR1BSNVMissense_Mutationrs376731426c.209N>Tp.Thr70Metp.T70MQ9Y6B6protein_codingdeleterious(0.04)benign(0.302)TCGA-AX-A06F-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
SAR1BSNVMissense_Mutationnovelc.264N>Ap.Asn88Lysp.N88KQ9Y6B6protein_codingdeleterious(0.03)benign(0.057)TCGA-AX-A1CE-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnspecificPaclitaxelSD
SAR1BSNVMissense_Mutationc.226N>Ap.Leu76Metp.L76MQ9Y6B6protein_codingdeleterious(0.03)probably_damaging(0.996)TCGA-B5-A11G-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1